Tramiprosate in mild-to-moderate Alzheimer's disease - A randomized, double-blind, placebo-controlled, multi-centre study (the alphase study)

Archives of Medical Science

Volumn 7, Issue 1, 2011, Pages 102-111

  Aisen, Paul S ^a   Gauthier, Serge ^b   Ferris, Steven H ^c,d   Saumier, Daniel ^e   Haine, Denis ^f   Garceau, Denis ^g   Duong, Anh ^f   Suhy, Joyce ^h   Oh, Joonmi ^h   Lau, Wan C ^h   Sampalis, John ^f,i  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^e MCGILL UNIVERSITY   (Canada)

^f INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^g BELLUS Health Inc   (Canada)

^h SYNARC INC   (United States)

ⁱ MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Alzheimer's disease; Amyloid; Disease modification; Tramiprosate; Volumetric MRI

Indexed keywords

CHOLINESTERASE INHIBITOR; HOMOTAURINE; MEMANTINE; PLACEBO;

ADULT; AGED; AGITATION; ALZHEIMER DISEASE; ANXIETY; ARTICLE; BACKACHE; BRAIN SIZE; CONGESTIVE HEART FAILURE; COUGHING; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FALLING; FATIGUE; FEMALE; HEADACHE; HEART INFARCTION; HIPPOCAMPUS; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SYNCOPE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

EID: 79952519404     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2011.20612     Document Type: Article

References (30)

1. Gandy S. The role of cerebral amyloid β accumulation in common forms of Alzheimer disease. J Clin Invest 2005; 115: 1121-9. (Pubitemid 40629026)
2. Canevari L, Abramov A, Duchen MR. Toxicity of amyloid B peptide: tales of calcium, mitochondria, and oxidative stress. Neurochem Res 2004; 29: 637-50. (Pubitemid 38295014)
3. Schaller BJ. Strategies for molecular imaging dementia and neurodegenerative diseases. Neuropsychiatr Dis Treat 2008; 4: 585-612. (Pubitemid 352037838)
4. Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 2004; 5: 677-85. (Pubitemid 39150139)
5. Gervais F, Paquette J, Morissette C, et al. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 2007; 28: 537-47. (Pubitemid 46282205)
6. th International Conference AD/PD, Salzburg, Austria, March 14-18, 2007.
7. th International Conference AD/PD, Salzburg, Austria, March 14-18, 2007.
8. Aisen PS, Saumier D, Briand R, et al. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 2006; 67: 1757-63. (Pubitemid 44900749)
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association, 2000.
10. McKhann G, Drachman D, Folskein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Word Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44.
11. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State" a practical method for grading the cognitive state of patients for the clinician. Psychiatr Res 1975; 12: 189-98.
12. Mohs RC, Cohen L. Alzheimer's Disease Assessment Scale (ADAS). Psychopharmacol Bull 1988; 24: 627-8. (Pubitemid 19054367)
13. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-4. (Pubitemid 23346995)
14. Schneider LS, Olin JT, Doody RS, et al. Validity and Reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Dis Assoc Disord 1997; 11 (Suppl. 2): S22-S32.
15. Cummings JL. The Neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology 1997;48: S10-S16. (Pubitemid 27232698)
16. Gélinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther 1999; 53: 471-81.
17. Gauthier S, Aisen PS, Ferris SH, et al. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. J Nutr Health Aging 2009; 13: 550-7.
18. Hsu YY, Schuff N, Du AT, et al, Comparison of automated and manual MRI volumetry of hippocampus in normal aging and dementia. J Magn Reson Imaging 2002; 16: 305-10. (Pubitemid 34920430)
19. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs. placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003; 289:2819-26. (Pubitemid 37430117)
20. Csernansky JG, Wang L, Joshi S, et al. Early DAT is distinguished from aging by high-dimensional mapping of the hippocampus. Neurology 2000; 55: 1636-43.
21. Dickerson BC, Goncharova I, Sullivan MP, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging 2001; 22: 747-54. (Pubitemid 33055614)
22. Du AT, Schuff N, Amend D, et al. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001; 71: 441-7. (Pubitemid 32906865)
23. Ezekiel F, Chao L, Kornak J, et al. Comparisons between global and focal brain atrophy rates in normal aging and Alzheimer's disease. Alzheimer Dis Assoc Disord 2004; 18: 196-201.
24. Jack CR Jr, Petersen, RC, Xu Y, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 2000; 55: 484-90.
25. Jack CR Jr, Slomkowski M, Gracon S, et al. MRI as a biomarker of disease progression in a therapeutic trial of melameline for AD. Neurology 2003; 60: 253-60. (Pubitemid 36152018)
26. Fox NC, Black RS, Gilman, S, et al. Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005; 64: 1563-72. (Pubitemid 40617692)
27. Hashimoto M, Kazui H, Matsumoto K, et al. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am J Psychiatry 2005; 162: 676-82.
28. Moffat SD, Szekely CA, Zonderman AB, et al. Longitudinal change in hippocampal volume as a function of apolipoprotein E genotype. Neurology 2000; 55: 134-6. (Pubitemid 30461016)
29. Mueller SG, Weiner MW. Selective effect of age, Apo e4, and Alzheimer's disease on hippocampal subfields. Hippocampus 2009; 19: 558-64.
30. Saumier D, Aisen PS, Gauthier S, et al. Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (Tramiprosate) experience. J Nutr Health Aging 2009; 13: 370-2.